Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin

Overview

Journal Intern Med

Specialty General Medicine

Date 2022 Jul 31

PMID 35908970

Authors

Kenta Hayashino

Junichi Zaitsu

Kazuya Kuraoka

Taizo Hirata

Affiliations

Soon will be listed here.

Abstract

Metaplastic breast cancer (MBC) is characterized by the histological presence of a mixture of epithelial and mesenchymal-like elements. However, MBC responds poorly to chemotherapy. Due to its rarity, there is no well-defined treatment for MBC. Herein, we report the case of a 56-year-old woman who underwent a mastectomy and was diagnosed with MBC with osseous differentiation classified as pT4N0M1. After the operation, she was treated with adriamycin and cisplatin, which are standard osteosarcoma treatments, resulting in a partial response. However, to determine the proper chemotherapy treatment, knowledge of the metaplastic elements of the tumor is required.

References

Vranic S, Stafford P, Palazzo J, Skenderi F, Swensen J, Xiu J . Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers. Clin Breast Cancer. 2020; 20(4):326-331.e1. DOI: 10.1016/j.clbc.2020.02.008. View

Edenfield J, Schammel C, Collins J, Schammel D, Edenfield W . Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution. Clin Breast Cancer. 2016; 17(1):e1-e10. DOI: 10.1016/j.clbc.2016.07.004. View

Song Y, Liu X, Zhang G, Song H, Ren Y, He X . Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013; 11:129. PMC: 3679991. DOI: 10.1186/1477-7819-11-129. View

Tse G, Tan P, Putti T, Lui P, Chaiwun B, Law B . Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006; 59(10):1079-83. PMC: 1861754. DOI: 10.1136/jcp.2005.030536. View

Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R . Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13(7):1537-45. DOI: 10.1200/JCO.1995.13.7.1537. View

Park H, Park S, Kim J, Lee J, Choi S, Park B . Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J. 2010; 51(6):864-9. PMC: 2995974. DOI: 10.3349/ymj.2010.51.6.864. View

Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W . Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011; 130(1):345-51. DOI: 10.1007/s10549-011-1686-9. View

Brown-Glaberman U, Graham A, Stopeck A . A case of metaplastic carcinoma of the breast responsive to chemotherapy with Ifosfamide and Etoposide: improved antitumor response by targeting sarcomatous features. Breast J. 2010; 16(6):663-5. DOI: 10.1111/j.1524-4741.2010.00975.x. View

Polamraju P, Haque W, Cao K, Verma V, Schwartz M, Klimberg V . Comparison of outcomes between metaplastic and triple-negative breast cancer patients. Breast. 2019; 49:8-16. PMC: 7375639. DOI: 10.1016/j.breast.2019.10.003. View

10.

Tzanninis I, Kotteas E, Ntanasis-Stathopoulos I, Kontogianni P, Fotopoulos G . Management and Outcomes in Metaplastic Breast Cancer. Clin Breast Cancer. 2016; 16(6):437-443. DOI: 10.1016/j.clbc.2016.06.002. View

11.

Cimino-Mathews A, Verma S, Figueroa-Magalhaes M, Jeter S, Zhang Z, Argani P . A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. Am J Clin Pathol. 2016; 145(3):365-72. DOI: 10.1093/ajcp/aqv097. View

12.

Penel N, Italiano A, Ray-Coquard I, Chaigneau L, Delcambre C, Robin Y . Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2011; 23(2):517-23. DOI: 10.1093/annonc/mdr138. View

13.

Moreno A, Lin Y, Bedrosian I, Shen Y, Babiera G, Shaitelman S . Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes. J Cancer. 2020; 11(6):1341-1350. PMC: 6995376. DOI: 10.7150/jca.40817. View

14.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin M, Singh P . Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat. 2017; 163(3):461-474. PMC: 5427146. DOI: 10.1007/s10549-017-4202-z. View

15.

Souhami R, Craft A, van der Eijken J, Nooij M, Spooner D, Bramwell V . Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350(9082):911-7. DOI: 10.1016/S0140-6736(97)02307-6. View

16.

Shah D, Tseng W, Martinez S . Treatment options for metaplastic breast cancer. ISRN Oncol. 2012; 2012:706162. PMC: 3388429. DOI: 10.5402/2012/706162. View

17.

Catroppo J, Lara J . Metastatic metaplastic carcinoma of the breast (MCB): an uncharacteristic pattern of presentation with clinicopathologic correlation. Diagn Cytopathol. 2001; 25(5):285-91. DOI: 10.1002/dc.2056. View

18.

Carter M, Hornick J, Lester S, Fletcher C . Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006; 30(3):300-9. DOI: 10.1097/01.pas.0000184809.27735.a1. View